Dihydroflavanol compound in radix ephedrae as well as preparation method and application of dihydroflavanol compound
By extracting and isolating the dihydroflavanol compound ephedrine T from ephedra root, the problems of high cost and dependence of existing PH treatment drugs have been solved, achieving a highly effective inhibition of pulmonary artery smooth muscle cell proliferation and expanding the medicinal value of ephedra root.
Patent Information
- Application Number
- CN202410981502.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-07-22
AI Technical Summary
Existing pulmonary artery disease (PH) treatment drugs are expensive, addictive, and lack safe and effective drugs to inhibit the proliferation of pulmonary artery smooth muscle cells.
Ephedrine T, a dihydroflavanol compound, was extracted from Ephedra roots and prepared by water decoction and multi-step chromatographic separation techniques. It was used to inhibit the malignant proliferation of pulmonary artery smooth muscle cells induced by hypoxia.
The prepared ephedrine T has high purity and significant anti-pulmonary hypertension activity, and can effectively inhibit the malignant proliferation of pulmonary artery smooth muscle cells, providing a safe and effective PH treatment option.
Smart Images

Figure CN118978505A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medicine, in particular to a dihydroflavanol compound in ephedra root and a preparation method and application thereof. Background Art
[0002] Pulmonary hypertension (PH) is a disease characterized by resting cytoplasmic free Ca2+ in pulmonary artery smooth muscle cells. 2+ A disease characterized by increased concentration, pulmonary vascular proliferation and remodeling, which will eventually lead to right ventricular failure and threaten the patient's life. Currently, the treatment drugs for PH mainly focus on vasodilation and inhibition of pulmonary artery smooth muscle cell proliferation, but they are expensive and highly dependent, so it is urgent to seek safer and more effective drugs for the prevention and treatment of PH.
[0003] Ephedra root, also known as bitter toon vegetable, was first seen in the "Compendium of Materia Medica". It is sweet, slightly astringent, flat, and belongs to the lung meridian. It has the effect of strengthening the exterior and stopping sweating. It is currently included in the "Chinese Pharmacopoeia" and is the dried root and rhizome of the plant Ephedra sinica Stapf. or Ephedra intermedia Schrenk et CA Mey. of the Ephedraceae Dumortier genus (EphedraTourn ex Linn.). The modern pharmacological activity of Ephedra root is mainly manifested in antiperspirant, antihypertensive, heart rate lowering and anti-tumor effects. Its main chemical components are alkaloids, flavonoids, esters, glycosides and organic acids. Due to the lack of research on the active ingredients of Ephedra root and its weak activity research, the development and utilization of Ephedra root has been seriously restricted. So is it possible to select ephedra root as the research object, conduct systematic extraction, separation and structural identification of its chemical components, and isolate a new dihydroflavanol compound, namely ephedra root phenol T, which can significantly inhibit the hypoxia-induced malignant proliferation of pulmonary arterial smooth muscle cells and prepare drugs against pulmonary hypertension? However, there has been no public report so far. Summary of the invention
[0004] In view of the above situation, in order to overcome the shortcomings of the prior art, the purpose of the present invention is to provide a dihydroflavanol compound in ephedra root and a preparation method and application thereof, which can effectively solve the problem of preparing dihydroflavanol compounds from ephedra root and realize the preparation of drugs for inhibiting hypoxia-induced malignant proliferation of pulmonary arterial smooth muscle cells and anti-pulmonary hypertension.
[0005] The technical solution provided by the present invention is a dihydroflavanol compound in the root of ephedra, which is ephedra root phenol T, and has the molecular structure formula:
[0006]
[0007] The preparation method is as follows: take the dried root and rhizome of Ephedra sinica, extract twice with water in an amount of 15 times the weight volume of Ephedra sinica by water decoction method, each time for 2 hours, the weight volume means that the solid is measured in kg and the liquid is measured in L, the root of Ephedra sinica extracted by water decoction is then extracted twice with ethanol heating and reflux, 1 kg of Ephedra sinica root is added with 4 L of ethanol each time, each time for 2 hours, the extract is concentrated under reduced pressure to obtain an extract, then dispersed and dissolved with water, extracted with petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence, and the solvent is recovered to obtain a petroleum ether part, a dichloromethane part, an ethyl acetate part and a n-butanol part;
[0008] The ethyl acetate fraction was separated from the blank silica gel by silica gel column chromatography to obtain the mixed silica gel, which was gradient eluted with dichloromethane-methanol in different volume ratios, concentrated under reduced pressure, and sprayed with anisaldehyde-concentrated sulfuric acid for detection, once every 7 ml, and the same fractions were combined to obtain fractions E1-E8 and E9;
[0009] Fraction E8 was separated by silica gel column chromatography, and then gradient eluted with dichloromethane-methanol in different volume ratios, concentrated under reduced pressure, and sprayed with anisaldehyde-concentrated sulfuric acid for detection once every 7 ml. The same fractions were combined to obtain fractions E8-1 to E8-5 and E8-6;
[0010] Fraction E8-5 was concentrated under reduced pressure and chromatographed on a Toyopearl HW-40C gel column, eluted with pure methanol, and sprayed with anisaldehyde-concentrated sulfuric acid for detection, once every 5 ml. The same fractions were combined to obtain fractions E8-5-1, E8-5-2, E8-5-3 to E8-5-6;
[0011] The fraction E-8-5-3 was separated by semi-preparative HPLC and loaded onto a chromatographic column with a mobile phase of methanol:water at a flow rate of 3 ml / min. The fractions at the retention time were collected and concentrated to dryness to obtain compound ephedrine T.
[0012] The ephedra root phenol T prepared by the method has anti-pulmonary hypertension activity and can be effectively used for preparing drugs for inhibiting hypoxia-induced malignant proliferation of pulmonary artery smooth muscle cells and anti-pulmonary hypertension.
[0013] The invention has abundant raw materials, is easy to operate in the preparation method, has good product quality, good extraction effect and high purity, and the obtained compound has anti-pulmonary hypertension activity, and can be used in the preparation of drugs for treating and inhibiting hypoxia-induced malignant proliferation of pulmonary artery smooth muscle cells and pulmonary hypertension, thus expanding the medicinal value of ephedra root and having huge economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The 1H-NMR spectrum (in 500MHz, DMSO-d6)) of the ephedra root phenol T of the present invention.
[0015] Figure 2 The 13C-NMR spectrum (in 125 MHz, DMSO-d6) of the ephedrine T of the present invention.
[0016] Figure 3 The DEPT 135 spectrum (in DMSO-d6) of ephedra root phenol T of the present invention.
[0017] Figure 4 The figure is the 1H-1H COSY spectrum (in DMSO-d6) of ephedra root phenol T of the present invention.
[0018] Figure 5 The HSQC spectrum (in DMSO-d6) of ephedra root phenol T of the present invention is shown.
[0019] Figure 6 The figure is the HMBC spectrum (in DMSO-d6) of ephedra root phenol T of the present invention.
[0020] Figure 7 The figure is the NOESY spectrum (in DMSO-d6) of ephedra root phenol T of the present invention.
[0021] Figure 8 The figure is the HR-ESI-MS spectrum (in MeOH) of ephedra root phenol T of the present invention.
[0022] Fig. 9 The IR spectrum (in MeOH) of ephedra root phenol T of the present invention is shown in FIG.
[0023] Fig.10 The figure is the UV spectrum (in MeOH) of ephedra root phenol T of the present invention.
[0024] Fig.11 The figure is the molecular structural formula of ephedrine T of the present invention.
[0025] Fig.12 The ephedra root phenol T of the present invention 1 H- 1 H COSY correlation and HMBC correlation plots.
[0026] Fig.13 It is the ECD spectrum of ephedra root phenol T of the present invention.
[0027] Fig.14 The effect of ephedra root phenol T on the cell survival rate in the malignant proliferation model of pulmonary artery smooth muscle cells induced by hypoxia chamber ( n=1.#P<0.05vsNC; *P<0.05vsM). DETAILED DESCRIPTION
[0028] The specific implementation modes of the present invention are described in detail below in combination with embodiments and specific situations.
[0029] The present invention can be specifically implemented by the following embodiments:
[0030] The present invention discloses a dihydroflavanol compound in the root of ephedra, which is ephedra root phenol T, and its molecular structure is shown in Fig.11 The preparation method is as follows: 40 kg of dried roots and rhizomes of Ephedra sinica are taken, extracted twice with 600 L of water by water decoction method, each time for 2 hours, the roots of Ephedra sinica extracted by water decoction are then extracted twice with 95% ethanol by volume concentration by heating and reflux, each time 1 kg of Ephedra sinica roots are added with 4 L of ethanol, each time for 2 hours, the extract is concentrated under reduced pressure to obtain 10.0 kg of extract, and then dispersed and dissolved in water, extracted with petroleum ether 5 times, each time 7 L; extracted with dichloromethane 10 times, each time 10 L; extracted with ethyl acetate 12 times, each time 10 L; extracted with n-butanol 6 times, each time 6 L, and the solvent is recovered to obtain 211.6 g of petroleum ether fraction, 245.1 g of dichloromethane fraction, 335.5 g of ethyl acetate fraction, and 62.5 g of n-butanol fraction;
[0031] 335.5 g of the ethyl acetate fraction was separated from 6000 g of blank silica gel by 100-200 mesh silica gel column chromatography to obtain 500 g of sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1, 3-4 days / each gradient, and each 400-500 ml was concentrated under reduced pressure and transferred to a long test tube, and sprayed with anisaldehyde-concentrated sulfuric acid for identification, and each 7 ml was identified once, as one test tube, and tubes 1-11 were combined as fractions. E1 (0.79 g), 12-20 tubes are fraction E2 (2.05 g), 21-26 tubes are fraction E3 (0.91 g), 27-34 tubes are fraction E4 (2.06 g), 35-52 tubes are fraction E5 (2.09 g), 53-57 tubes are fraction E6 (3.06 g), 58-60 tubes are fraction E7 (2.12 g), 61-125 tubes are fraction E8 (91.86 g), 126-151 tubes are fraction E9 (50.0 g);
[0032] Fraction E8 (91.86 g) was separated by 200-300 mesh silica gel column chromatography, and gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 10:1, and 1:1, 1-2 days / each gradient, and concentrated under reduced pressure every 300-400 ml and transferred to a long test tube, and sprayed with anisaldehyde-concentrated sulfuric acid for detection, and detected once every 7 ml, and one test tube, 1-2 tubes were combined into fraction E8-1 (44.59 mg), 3-6 tubes were combined into fraction E8-2 (157.44 mg), 7-15 tubes were combined into fraction E8-3 (171.89 mg), 16-32 tubes were combined into fraction E8-4 (200.56 mg), 33-38 tubes were combined into fraction E8-5 (502.91 mg), and 39-51 tubes were combined into fraction E8-6 (2.31 g);
[0033] Fraction E8-5 (502.91 mg) was concentrated under reduced pressure and chromatographed on a Toyopearl HW-40C gel column, eluted with pure methanol, and sprayed with anisaldehyde-concentrated sulfuric acid for detection. Every 5 ml was detected once, and a test tube was formed. Tubes 2-6 were combined into fraction E8-5-1 (91.59 mg), tubes 7-10 were combined into fraction E8-5-2 (174.71 mg), tubes 11-12 were combined into fraction E8-5-3 (34.38 mg), tubes 13-18 were combined into fraction E8-5-4 (58.35 mg), tubes 19-22 were combined into fraction E8-5-5 (22.92 mg), and tubes 23-30 were combined into fraction E8-5-6 (32.45 mg);
[0034] E-8-5-3 (34.38 mg) was separated by semi-preparative HPLC. The upper specification model is: 250×10 mm, particle size 5 μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 48:52, flow rate is 3ml / min, collection retention time t R = The fraction from 21 to 23 min was concentrated to dryness to obtain compound ephedrine T (4.06 mg, purity: 98.6%).
[0035] According to the method given in the above embodiment, any amount of compound can be prepared as needed. The given embodiment is only used to illustrate the specific implementation mode of the present invention, rather than to limit the protection scope of the present invention. The technical core protected by the present invention is the compound, and the compound can be prepared into any required amount of ephedrine T according to actual needs.
[0036] The invention has abundant raw materials, easy-to-operate preparation method, good product quality, good extraction effect, high purity, and the obtained compound has anti-pulmonary hypertension activity, and can be used in the preparation of drugs for treating hypoxia-induced malignant proliferation of pulmonary artery smooth muscle cells and pulmonary hypertension, and has achieved very good beneficial technical effects through experiments. The relevant information is as follows:
[0037] 1. Experimental instruments and test drugs.
[0038] The nuclear magnetic resonance was performed using a Bruker AVANCEⅢ500 nuclear magnetic resonance instrument (TMS internal standard) (Bruker), the infrared spectroscopy was performed using a Nicolet is 10 Microscope Spectrometer (Thermo Scientific, USA), the high-resolution mass spectrometry was performed using a Bruker maxis HD mass spectrometer, the ultraviolet spectroscopy was performed using a Shimadzu UV-2401PC apparatus, a LC50 high-pressure preparative liquid chromatograph, a UV200 ultraviolet detector [Sepures (Beijing) Technology Co., Ltd.], and a 5C 18 -MS-Ⅱ chromatographic column (250×10mm.DS-5μm,12nm) (YMC Co., Ltd.), and the rest include N-1100 rotary evaporator (Shanghai Ailang Instrument Co., Ltd.), A-1000S water flow vacuum pump (Shanghai Ailang Instrument Co., Ltd.), N-1111 chilled water circulation device (Shanghai Ailang Instrument Co., Ltd.), FDU-2110 freeze dryer (Shanghai Ailang Instrument Co., Ltd.), DFZ-60508 vacuum drying oven (Shanghai Yiheng Scientific Instrument Co., Ltd.), AB204-N 1 / 10,000 precision analytical balance (METTLERTOLEDO), iMARK microplate reader (BIO-RAD, USA), carbon dioxide incubator (Thermo, USA), clean bench (Sujing Group), small high-speed refrigerated centrifuge (Eppendorf, Germany).
[0039] RPASMC cells were purchased from Beina Biotechnology Co., Ltd.; fetal bovine serum (Sijiqing 11011-8611, China); tertiary antibodies (Beijing Solebold Technology Co., Ltd. P1410); trypsin (Beijing Solebold Technology Co., Ltd. T8150); DMSO (cell culture medium) (Beijing Solebold Technology Co., Ltd. D8371); MTT thiazole blue (Nanjing Jiancheng Biological Research Institute M818079); penicillin-streptomycin-gentamicin mixture (Beijing Solebold Technology Co., Ltd. P1410); column chromatography filler Toyopearl HW-40C (Mitsubishi Chemical Corporation, Japan), silica gel H (100-200 mesh) used in column chromatography was produced by Qingdao Ocean Chemical Plant, the chromatographic pure reagents used were produced by Tianjin Siyou Fine Chemicals Co., Ltd., and the analytical pure reagents used were produced by Beijing Chemical Plant and Tianjin Third Chemical Reagent Factory.
[0040] The Ephedra sinica roots selected for this project were purchased from the Bozhou medicinal materials market in May 2021. They were identified by Professor Dong Chengming of the School of Pharmacy as the dried roots and rhizomes of the Ephedraceae plant Ephedra sinica Stapf. The plant specimen (NO.20210517) is preserved in the Traditional Chinese Medicine Chemical Extraction and Separation Laboratory of Henan University of Traditional Chinese Medicine.
[0041] 2. Structural identification.
[0042] Ephedra root phenol T yellow amorphous powder (CH3OH), HR-ESI-MS gives quasi-molecular ion peak m / z: 325.0674 [M+Na] + (Calcd.325.0682), the molecular formula is determined to be C 16 H 14 O6. UV(CH3OH)λ max (logε); 201(3.02), 297(2.63)nm; IRν max ;3266, 1637, 1518, 1448, 1205, 1032cm -1 wait; 1 HNMR (DMSO-d6, 500 MHz) and 13 C NMR (DMSO-d6, 125 MHz) data are shown in Table 1.
[0043] Table 1 NMR spectrum data of ephedra root phenol T
[0044]
[0045] a Recorded in DMSO-d6
[0046] The molecular structure is:
[0047]
[0048] Named ephedra root phenol T.
[0049] 3. Activity detection
[0050] RPASMC cells in the logarithmic growth phase were cultured at 1×10 4The cells were inoculated into a 96-well plate at a density of 10 cells / well, and a malignant proliferation model of pulmonary artery smooth muscle cells was established by inducing a hypoxic chamber. A normal (NC) group, a model (M) group, and a drug-treated group were established. The next day, 200 μL of culture medium was given to the NC group and the M group, and the drug-treated group was given ephedra root phenol K compound (5 μM). The M group and the drug-treated group were placed in a hypoxic chamber for 72 hours for modeling, and then the MTT experiment was performed to detect cell viability. 20 mL of MTT solution was added to each well and cultured for 4 hours. The supernatant was discarded and 150 mL of DMSO solution was added. The plate was shaken on a vibrating machine for 10 minutes to fully dissolve the crystals. The absorbance (OD value) of each well was measured at a wavelength of 490 nm using an enzyme marker.
[0051] Activity test results:
[0052] Table 2 Effects of ephedra root phenol K on the hypoxia-induced malignant proliferation model of pulmonary artery smooth muscle cells. x±sd, n=4.
[0053] Group Dosage (μmol·L-1) Whether there is hypoxia Cell viability NC Group - no 1.000±0.055 Group M - yes <![CDATA[1.172±0.094 # ]]> Drug group 5 yes 0.9782±0.152*
[0054] Note: #P<0.05 compared with NC group; *p<0.05 compared with M group
[0055] The inhibitory effect of compound 1 (i.e., ephedra root phenol T of the present invention, the same below) on the malignant proliferation of pulmonary artery smooth muscle cells induced by hypoxia chamber was detected by MTT method. The results are as follows Fig.14 As shown, compared with the normal control group, the proliferation level of RPASMC cells in the model group was significantly increased (P<0.05); compared with the model group, compound 1 could significantly inhibit the abnormal proliferation of RPASMC cells (p<0.05), and had potential anti-pulmonary hypertension activity.
[0056] It can be clearly seen from the above that the invention has abundant raw materials, easy preparation method, good product quality, good extraction effect, high yield, purity up to 98.6%, and the obtained compound has anti-pulmonary hypertension activity. The obtained compound has anti-pulmonary hypertension activity, and can be used in the preparation of drugs for treating hypoxia-induced malignant proliferation of pulmonary arterial smooth muscle cells and pulmonary hypertension. It is an innovation in drugs for treating pulmonary hypertension, has practical clinical application value, opens up new uses of ephedra root, and has huge economic and social benefits.
Claims
1. A dihydroflavanol compound in the root of ephedra, the compound is ephedra root phenol T, and the molecular structure formula is: 。 2. The method for preparing dihydroflavanol compounds in the root of Ephedra according to claim 1, characterized in that: Take the dried root and rhizome of Ephedra sinica, extract twice with water 15 times the weight volume of Ephedra sinica by water decoction method, each time for 2 hours, the weight volume means that the solid is measured in kg and the liquid is measured in L, the root of Ephedra sinica extracted by water decoction is then extracted twice with ethanol heating and reflux, each time 1kg of Ephedra sinica root is added with 4L of ethanol, each time for 2 hours, the extract is concentrated under reduced pressure to obtain an extract, then dispersed and dissolved with water, extracted with petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence, and the solvent is recovered to obtain a petroleum ether part, a dichloromethane part, an ethyl acetate part and a n-butanol part; The ethyl acetate fraction was separated from the blank silica gel by silica gel column chromatography to obtain the mixed silica gel, which was gradient eluted with dichloromethane-methanol in different volume ratios, concentrated under reduced pressure, and sprayed with anisaldehyde-concentrated sulfuric acid for detection, once every 7 ml, and the same fractions were combined to obtain fractions E1-E8 and E9; Fraction E8 was separated by silica gel column chromatography, and then gradient eluted with dichloromethane-methanol in different volume ratios, concentrated under reduced pressure, and sprayed with anisaldehyde-concentrated sulfuric acid for detection once every 7 ml. The same fractions were combined to obtain fractions E8-1 to E8-5 and E8-6; Fraction E8-5 was concentrated under reduced pressure and chromatographed on a Toyopearl HW-40C gel column, eluted with pure methanol, and spray-detected with anisaldehyde-concentrated sulfuric acid, once every 5 ml. The same fractions were combined to obtain fractions E8-5-1, E8-5-2, E8-5-3 to E8-5-6; The fraction E-8-5-3 was separated by semi-preparative HPLC and loaded onto a chromatographic column with a mobile phase of methanol:water at a flow rate of 3 ml / min. The fractions at the retention time were collected and concentrated to dryness to obtain compound ephedrine T.
3. The method for preparing dihydroflavanol compounds in the root of Ephedra according to claim 2, characterized in that: 40 kg of dried roots and rhizomes of Ephedra sinica were extracted twice with 600 L of water by water decoction method, each time for 2 hours. The roots of Ephedra sinica after water decoction were then extracted twice with 95% ethanol by heating and reflux, each time 1 kg of Ephedra sinica roots were added with 4 L of ethanol, each time for 2 hours. The extract was concentrated under reduced pressure to obtain 10.0 kg of extract, which was then dispersed and dissolved in water. It was extracted with petroleum ether 5 times, each time with 7 L; extracted with dichloromethane 10 times, each time with 10 L; extracted with ethyl acetate 12 times, each time with 10 L; extracted with n-butanol 6 times, each time with 6 L, and the solvent was recovered to obtain 211.6 g of petroleum ether, 245.1 g of dichloromethane, 335.5 g of ethyl acetate, and 62.5 g of n-butanol. The ethyl acetate fraction was separated by 100-200 mesh silica gel column chromatography. 6000 g of blank silica gel was obtained to obtain 500 g of sample silica gel, which was gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 20:1, 10:1, 5:1, and 3:1, 3-4 days / each gradient. Every 400-500 ml was concentrated under reduced pressure and transferred to a long test tube, and anisaldehyde-concentrated sulfuric acid was used for spray detection. Every 7 ml was detected for one test tube. Tubes 1-11 were combined as fraction E1 0.79 g, tubes 12-20 were combined as fraction E2 2.05 g, tubes 21-26 were combined as fraction E3 0.91 g, tubes 27-34 were combined as fraction E4 2.06 g, tubes 35-52 were combined as fraction E5 2.09 g, tubes 53-57 were combined as fraction E6 3.06 g, and tubes 58-60 were combined as fraction E7 2.12 g, tubes 61-125 were fraction E8 91.86 g, and tubes 126-151 were fraction E9 50.0 g; Fraction E8 was separated by 200-300 mesh silica gel column chromatography, and gradient eluted with dichloromethane-methanol in a volume ratio of 50:1, 30:1, 10:1, and 1:1, 1-2 days / each gradient, and each 300-400 ml was concentrated under reduced pressure and transferred to a long test tube, and sprayed with anisaldehyde-concentrated sulfuric acid for identification, and each 7 ml was identified once, and one test tube was formed, and tubes 1-2 were combined into fraction E8-1 44.59 mg, tubes 3-6 were combined into fraction E8-2 157.44 mg, tubes 7-15 were combined into fraction E8-3 171.89 mg, tubes 16-32 were combined into fraction E8-4 200.56 mg, tubes 33-38 were combined into fraction E8-5 502.91 mg, and tubes 39-51 were combined into fraction E8-6 2.31 g; Fraction E8-5 was concentrated under reduced pressure and chromatographed on a Toyopearl HW-40C gel column, eluted with pure methanol, and sprayed with anisaldehyde-concentrated sulfuric acid for identification. Every 5 ml was identified as one test tube, and tubes 2-6 were combined into fraction E8-5-1 (91.59 mg), tubes 7-10 were combined into fraction E8-5-2 (174.71 mg), tubes 11-12 were combined into fraction E8-5-3 (34.38 mg), tubes 13-18 were combined into fraction E8-5-4 (58.35 mg), tubes 19-22 were combined into fraction E8-5-5 (22.92 mg), and tubes 23-30 were combined into fraction E8-5-6 (32.45 mg); E-8-5-3 was separated by semi-preparative HPLC, the upper specification model is: 250×10mm, particle size 5μm, pore size 12 nm 5C 18 -MS-Ⅱ chromatographic column, mobile phase is methanol: water = 48:52, flow rate is 3ml / min, collection retention time t R = 21-23 min fraction was concentrated and dried to obtain 4.06 mg of compound ephedrine T with a purity of 98.6%.
4. Use of the dihydroflavanol compound ephedrae T in the root of ephedra according to claim 1 in the preparation of a drug for inhibiting hypoxia-induced malignant proliferation of pulmonary artery smooth muscle cells.
5. Use of the dihydroflavanol compound ephedrin T in the root of ephedra according to claim 1 in the preparation of an anti-pulmonary hypertension drug.
Citation Information
Patent Citations
Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
CN102480951A
Method for extracting compound 1, 8-terpinenediol from ephedra herb stems and application of compound 1, 8-terpinenediol
CN115745745A
Aryl naphthalene phenolic acid compound extracted from radix ephedrae as well as preparation method and application of aryl naphthalene phenolic acid compound
CN118084855A
Pharmaceutical composition for the prevention ortreatment of Hypoxia-induced pulmonary arterialhypertension comprising Rosiglitazone as an activeingredient
KR1020080010150A
Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
US20190015444A1
